nivolumab,ipilimumab
bms
['ca,022,001', 'nivo', 'nivolumab', 'baron', 'ipilimumab', 'ca,022,i']
obesity may be associated with an increased incidence of mild or moderate immune-related adverse events among patients receiving immune checkpoint inhibitors. 
On the road!
Pursuing to improve global health through sharing knowledge, cancer prevention, and care.  
Medical oncologist @AnkaraUni